PRAMEF4

Across TCGA pan-cancer cohorts, PRAMEF4 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of PRAMEF4’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where PRAMEF4 RNA is repressed in tumor relative to normal tissue. In most cancer types PRAMEF4 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

BRCA and LIHC are the cancer types where PRAMEF4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRAMEF4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	−0.002	.027	4	view →
LIHC	All	All	+0.592	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

PRAMEF4–BRCA

Open the BRCA breakdown →